COMMUNIQUÉS West-GlobeNewswire

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
31/03/2025
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage [...]
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
31/03/2025
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline [...]
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
31/03/2025
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of [...]
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
31/03/2025
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies [...]
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
31/03/2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical [...]
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
31/03/2025
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses [...]
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
31/03/2025
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements [...]
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
31/03/2025
BX211 was safe and well-tolerated BX211 produced sustained and statistically significant 1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13) , with a separation from placebo starting [...]
Glucofreedom Drops Reviews (EXPOSED) Gluco Revive BloodSugar Control ORDER NOW!
31/03/2025
AURORA, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- The maximum number of people are seen to have blood sugar these days. While for many the reason is not caring for their health as it should be, the other reason includes [...]
SBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ Expansion
31/03/2025
TOKYO, March 31, 2025 (GLOBE NEWSWIRE) -- Shonan Beauty Clinic, supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical," or the "Company") in management services, today announced the expansion [...]
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
31/03/2025
MILAN, March 31, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), announces the publication [...]
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
31/03/2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company [...]
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
31/03/2025
Conférence téléphonique et diffusion en direct sur Internet le jeudi 3 avril 2025 à 14 h 00 CEST / 8 h 00 EDT PARIS et CAMBRIDGE, Mass., 31 mars 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la [...]
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
31/03/2025
BASEL, Switzerland, March 31, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV [...]
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
31/03/2025
Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare [...]
Valneva soumet à la MHRA une demande d’élargissement de l’indication aux adolescents pour son vaccin contre le chikungunya IXCHIQ®
31/03/2025
Saint Herblain (France), le 31 mars 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui avoir soumis une demande d’élargissement de l’indication de son [...]
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
31/03/2025
After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of Novartis Karen Hale to drive the next phase of enterprise [...]
Opthea Announces Decision to Discontinue Wet AMD Trials
31/03/2025
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to [...]

Pages